Annals of Urologic Oncology

Table of Contents

  • Robot-Assisted Radical Cystectomy: State of Art and Future Perspectives

    Riccardo Mastroianni, Giuseppe Simone

    Bladder cancer (BC) remains one of the most common cancer worldwide. Radical cystectomy (RC) and pelvic lymph node dissection (PLND) with urinary diversion (UD) is still considered the gold standard treatment for non-metastatic muscle invasive bladder cancer (MIBC) and for recurrent non-muscle invasive disease. The open approach remains the reference option of treatment for RC, even if robotic sur...

    REVIEW | Published: 26 Dec 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 50-56   PDF(6080Kb)

  • Progress in Research on Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Bladder Cancer

    Wei-Ming Fang, Chun Chen

    Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) was first discovered in 1987 and confirmed to be a protein that is mainly expressed on the surface of activated lymphocytes. CTLA-4 is expressed on the surface of T cells and binds to B7 expressed on antigen presenting cells (APCs) to potentially play a role in inhibiting lymphocyte proliferation. Inhibitors of CTLA-4 were developed to promote t...

    REVIEW | Published: 24 Jan 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 57-63   PDF(781KB)

  • Measurement of DNA Damage in Bladder Cancer Patients by Alkaline Comet Assay

    Jahidul Islam, Yearul Kabir

    Bladder cancer is the most common cancer of the urinary tract. This is the first attempt to use alkaline comet assay to evaluate DNA damage in Bangladeshi bladder cancer patients. The results of this study may emphasize to use ACA for routine DNA damage detection, which could be used as a prognostic biomarker of bladder cancer....

    RESEARCH | Published: 29 Dec 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 64-70   PDF(1020Kb)

  • Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises

    Sabeeh‑ur‑Rehman Butt, Muhammad S Khan ... Anna Patrikidou

    As research focus in oncology has recently shifted to immunomodulation, the era of introduction of immunotherapeutic agents in the management of prostate cancer has just begun. With the success of checkpoint blockade drugs in certain advanced tumours, ongoing efforts are aimed at identification and validation of new actionable immune targets to consolidate and expand the initial success in other t...

    REVIEW | Published: 15 Sep 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 71-88   PDF(1680KB)

  • Mutations in Cancer Driver Genes: An Insight into Prostate Cancer Progression

    Sahdeo Prasad, Sanjay K Srivastava

    Prostate cancer is one of the most common uro-oncological disease in men and is globally leading cause of cancer related deaths in males. The somatic mutation has a strong link in the occurrence of cancer. Mutation in the oncogenes and tumor suppressor genes that alter key cellular functions can lead to prostate cancer initiation and progression. Whole genome sequencing has identified numerous gen...

    REVIEW | Published: 22 Sep 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 89-95    PDF(568KB)

  • Noncoding RNAs and Its Implication as Biomarkers in Renal Cell Carcinoma: A Systematic Analysis

    Shiv Verma, Sanjay Gupta

    Renal cell carcinoma (RCC) is one of the most devastating disease with higher mortality rates. It comprises several subtypes exhibiting distinct histological features and clinical staging. Despite recent advancement in understanding the biology of RCC success in treatment rates remains dismal. This may be partly due to lack of specific biomarkers for early detection/prognosis and poor clinical out...

    REVIEW | Published: 05 Apr 2019

    Annals of Urologic Oncology, Volume 2 , Issue 2

    Pages: 96-106   PDF(1210KB)